How would you treat a patient with HR+,HER2- metastatic breast cancer with a gBRCA mutation who has progressed on endocrine therapy with a new pericardial effusion?

Answer from: Medical Oncologist at Academic Institution

Assuming it is malignant pericardial effusion, and she has had "local therapies" such as pericardial window, if clinically indicated to prevent tamponade, then there two FDA-approved PARP inhibitors, talazoparib (Litton NEJM 2018) and olaparib (Robson NEJM 2017) for this setting. Both trials were of...

Comments

Medical Oncologist at Hennepin County Medical Center
Would you also consider to start her on carbo/Taxo...

Medical Oncologist at Icahn School of Medicine at Mount Sinai
No, I would try the PARP inhibitors, as they were ...

Answer from: Medical Oncologist at Community Practice

There is some retrospective data showing slightly worst outcomes in gBRCAm patients. Combinations trial for PARPi + CDK4/6i + ET

Please select the option that best describes you:

How would you treat a patient with HR+,HER2- metastatic breast cancer with a gBRCA mutation who has progressed on endocrine therapy with a new pericardial effusion?

Related Questions